Clinical trials
Adaptive Radiotherapy clinical trials
Below are recruiting adaptive radiotherapy clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07337876RecruitingPhase 2
Avoiding surgery for rectal cancer with precise radiation
This trial tests a new way to give high-dose radiation to rectal cancer tumors while avoiding the bladder and bowels. The goal is to cure the cancer without removing the rectum, so you may keep normal bowel function.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07415356Recruiting
Adaptive radiation for lymph node tumors that have spread
This trial tests a new way to deliver targeted radiation for cancer that has spread to lymph nodes in the belly or pelvis. The radiation dose is adjusted during each session to better hit the tumor while protecting healthy tissue.
Rotterdam, South HollandAges 18 years+ - NCT06355050Recruiting
Short, intense radiation for prostate cancer
This trial tests a very short course of daily radiation that adapts to your body's changes. It aims to be just as effective as standard treatment but more convenient.
JenaAges 18–120 - NCT05183074Recruiting
MRI-guided focused radiation for prostate cancer
This trial tests a newer way to plan and deliver radiation for prostate cancer using real-time MRI guidance. It may help by aiming high-dose treatment precisely while treating nearby disease and (in some cases) limited metastatic spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07221058RecruitingPhase 1
Adaptive radiation boost study for rectal cancer
This study tests whether giving an extra, targeted radiation dose (adaptive radiation boost) after standard treatment can improve outcomes for people with rectal cancer. You may be eligible if you have stage T2-3 N0-1 rectal cancer and can undergo MRI scans and certain chemotherapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07324798Recruiting
Adaptive Radiation Therapy for Genitourinary Cancers
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for people with urological cancers. It aims to adjust the radiation beam in real time to better target the tumor and protect healthy tissues, which may lead to fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06041555Recruiting
MRI-guided radiotherapy study for five cancer types
This study collects MRI scans and treatment data from patients getting MRI-guided radiotherapy for certain cancers. It aims to improve radiation treatment planning using imaging and biological information.
LyonAges 18 years+ - NCT06137274RecruitingPhase 2
Adaptive radiation boost for head and neck cancer
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
Tampa, FloridaAges 18 years+ - NCT06345287RecruitingPhase 2
Adaptive radiotherapy after immunotherapy for head and neck cancer
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
BeijingAges 18–75 - NCT06053086Recruiting
Adaptive radiation therapy for breast cancer patients at high risk
This trial tests a new way to deliver radiation therapy that adapts to each patient's body changes during treatment. It is for women who had breast cancer surgery and need radiation to the whole breast and nearby lymph nodes, and who have been identified as being at risk for breast fibrosis.
MontpellierAges 18 years+ - NCT06691776Recruiting
Adaptive radiotherapy for five cancer types
This trial tests whether a newer type of daily CT scan (CBCT-guided adaptive radiotherapy) can safely and accurately deliver radiation to cancers of the prostate, cervix, bladder, lung, or head and neck. The goal is to better target the tumor and reduce side effects.
AmsterdamAges 18 years+ - NCT07524426Recruiting
Local Radiation Therapy for Bladder Cancer Not Suitable for Surgery
This trial tests whether focused radiation therapy directed at the bladder can help patients with muscle-invasive bladder cancer who are not candidates for surgical removal or have chosen not to have surgery. The goal is to see if this approach can control the cancer and improve quality of life.
Umeå, Västerbotten CountyAges 18 years+ - NCT07348887Recruiting
Daily adaptive radiotherapy for head and neck cancer to spare salivary glands
This trial tests a new daily adaptive radiotherapy technique that aims to spare the submandibular salivary glands during head and neck cancer treatment. It may help reduce dry mouth after radiation.
Toronto, OntarioAges 18 years+ - NCT06116019Recruiting
Online adaptive radiotherapy for cancer patients
This trial tests a new radiation therapy machine that adjusts the radiation plan in real-time based on changes in your body. It may help make treatment more precise and reduce side effects.
BerlinAges 18 years+ - NCT05833867RecruitingPhase 1
Bladder cancer trial combining radiation and Sacituzumab
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
Cleveland, OhioAges 18 years+ - NCT06831032Recruiting
Adaptive radiation for prostate cancer in lymph nodes
This trial tests a type of targeted radiation (SBRT) for prostate cancer that has come back only in certain lymph nodes around the belly or hip. The goal is to see if adapting the radiation plan during treatment can make the response last longer.
Toronto, OntarioAges 18 years+ - NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT06840665RecruitingPhase 2
Radiation plus immunotherapy and chemo for rectal cancer
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06604533Recruiting
MRI-guided radiation for abdominal cancer spread
This trial tests if MRI-guided radiation can precisely target and treat cancer that has spread to a few spots in the abdomen (like the liver or lymph nodes). It's for people whose original cancer is under control and who have up to 5 small tumors in up to 2 body areas.
Darlinghurst, New South WalesAges 18 years+ - NCT04771806Recruiting
MRI-guided adaptive radiation for high-grade brain tumors
This study uses repeated MRI scans with a contrast dye to help doctors tailor (adapt) your radiation treatment over time for a high-grade glioma. It may help improve how accurately radiation targets the tumor as it changes.
Houston, TexasAges 18 years+ - NCT05348486Recruiting
Adaptive radiation planning using FMISO imaging for head and neck cancer
This trial tests a way to personalize radiation treatment using a special scan (FMISO) to improve targeting in certain head and neck cancers. It is designed for people who are newly diagnosed and ready for standard curative (definitive) chemoradiation or faster radiation schedules.
BrnoAges 18 years+ - NCT05387603RecruitingPhase 3
Targeted radiation for certain advanced neuroendocrine tumors
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
GothenburgAges 18 years+ - NCT06185062Recruiting
Pelvic cancer registry for online adapted radiotherapy
This study collects data from patients receiving a type of radiation therapy that is adjusted in real-time. It aims to learn more about how well this approach works for pelvic and chest tumors.
GöttingenAges 18 years+ - NCT06568705RecruitingPhase 2
Shorter adaptive radiation for early breast cancer
This trial tests a shorter, more targeted course of daily radiation for early-stage breast cancer. The radiation plan is adjusted each day to better fit your body, which may reduce side effects.
BeijingAges 35–70
Hear when a new Adaptive Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adaptive radiotherapy?
- Yes. Clin2 currently lists 76 recruiting adaptive radiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adaptive radiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adaptive radiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.